OUTREACH: Urine Analysis and Antihypertensive Treatment

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 18, 2018

Primary Completion Date

August 4, 2023

Study Completion Date

September 30, 2023

Conditions
HypertensionAdherence, Medication
Interventions
OTHER

HPLC-MS/MS-guided intervention

The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment

OTHER

Standard care

Standard care for hypertensive patients

Trial Locations (12)

Unknown

University College London Hospitals NHS Foundation Trust, London

Homerton Hospital, London

St Bartholomews Hospital, London

M13 9WL

Manchester Royal Infirmary, Manchester

DD2 1SY

Ninewells Hospital, Dundee

DE24 0GE

Alvaston Medical Centre, Derby

KT17 1HB

Epsom & St. Helier University Hospitals NHS Trust, Epsom

LE3 9QP

Glenfield General Hospital, Leicester

NW3 2QG

Royal Free Hospital, London

SE1 7EH

Guy's and St Thomas' Hospital, London

NG9 6DX

Chilwell Valley and Meadows Practice, Nottingham

BH15 2JB

University Hospitals Dorset NHS Foundation Trust, Poole

Sponsors
All Listed Sponsors
collaborator

British Heart Foundation

OTHER

collaborator

Manchester Academic Health Science Centre

OTHER

collaborator

Omron Healthcare Co., Ltd.

INDUSTRY

lead

University of Manchester

OTHER

NCT03293147 - OUTREACH: Urine Analysis and Antihypertensive Treatment | Biotech Hunter | Biotech Hunter